Mobile AI Market Projected to Hit USD 80.5 Billion at a 23-02-2023, 20:50

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia 21-09-2024, 15:15

Canada’s Unions Welcome Improved Long-Term Care Standard — 1-02-2023, 03:09